.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,342,014

« Back to Dashboard

Details for Patent: 7,342,014

Title:Diamine derivatives
Abstract: A compound represented by the general formula (1): Q.sup.1-Q.sup.2-T.sup.0-N(R.sup.1)-Q.sup.3-N(R.sup.2)-T.sup.1-Q.sup.4 (1) wherein R.sup.1 and R.sup.2 are hydrogen atoms or the like; Q.sup.1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q.sup.2 is a single bond or the like; Q.sup.3 is a group ##STR00001## in which Q.sup.5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T.sup.0 and T.sup.1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
Inventor(s): Ohta; Toshiharu (Tokyo, JP), Komoriya; Satoshi (Tokyo, JP), Yoshino; Toshiharu (Tokyo, JP), Uoto; Kouichi (Tokyo, JP), Nakamoto; Yumi (Tokyo, JP), Naito; Hiroyuki (Tokyo, JP), Mochizuki; Akiyoshi (Tokyo, JP), Nagata; Tsutomu (Tokyo, JP), Kanno; Hideyuki (Tokyo, JP), Haginoya; Noriyasu (Tokyo, JP), Yoshikawa; Kenji (Tokyo, JP), Nagamochi; Masatoshi (Tokyo, JP), Kobayashi; Syozo (Tokyo, JP), Ono; Makoto (Tokyo, JP)
Assignee: Daiichi Pharmaceutical Co., Ltd. (Tokyo, JP)
Filing Date:Feb 09, 2004
Application Number:10/773,344
Claims:1. A compound having a structural formula, including a salt thereof, selected from the group consisting of: ##STR00852##

2. A composition comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier.

3. The composition according to claim 2, wherein said composition further comprises at least one pharmaceutically acceptable additive selected from the group consisting of fillers, extenders, binders, disintegrating agents, dissolution aids/accelerators, suspending agents, emulsifying agents, wetting agents, stabilizers, and preservatives.

4. The composition according to claim 2, wherein said composition is in the form of a tablet, a granule, a capsule, a powder, a solution, a suspension, an emulsion, an oil, a syrup, an elixir, an ointment, a gel, a cream, a lotion, a spray, or a plaster.

5. The composition according to claim 2, wherein said composition is suitable for oral, topical, or injection administration.

6. A process for preparing a composition comprising combining at least one compound according to claim 1 with a pharmaceutically acceptable carrier.

7. The process according to claim 6, wherein said process further comprises combining with said at least one compound and said pharmaceutically acceptable carrier, at least one pharmaceutically acceptable additive selected from the group consisting of fillers, extenders, binders, disintegrating agents, dissolution aids/accelerators, suspending agents, emulsifying agents, wetting agents, stabilizers, and preservatives.

8. A method of inhibiting activated blood coagulation factor X comprising administering to a mammal in need thereof a effective amount of the composition according to claim 2.

9. The method according to claim 8, wherein said effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

10. The method according to claim 8, wherein said effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

11. The method according to claim 8, wherein the administration of said composition ranges from one to four times per day.

12. A method of treating thrombosis or embolism comprising administering to a mammal in need thereof a effective amount of the composition according to claim 2.

13. The method according to claim 12, wherein said effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

14. The method according to claim 12, wherein said effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

15. The method according to claim 12, wherein the administration of said composition ranges from one to four times per day.

16. A compound having a stereochemical structural formula, including a salt thereof, selected from the group consisting of: ##STR00853##

17. A composition comprising at least one compound according to claim 16 and a pharmaceutically acceptable carrier.

18. The composition according to claim 17, wherein said composition further comprises at least one pharmaceutically acceptable additive selected from the group consisting of fillers, extenders, binders, disintegrating agents, dissolution aids/accelerators, suspending agents, emulsifying agents, wetting agents, stabilizers, and preservatives.

19. The composition according to claim 17, wherein said composition is in the form of a tablet, a granule, a capsule, a powder, a solution, a suspension, an emulsion, an oil, a syrup, an elixir, an ointment, a gel, a cream, a lotion, a spray, or a plaster.

20. The composition according to claim 17, wherein said composition is suitable for oral, topical, or injection administration.

21. A process for preparing a composition comprising combining at least one compound according to claim 16 with a pharmaceutically acceptable carrier.

22. The process according to claim 21, wherein said process further comprises combining with said at least one compound and said pharmaceutically acceptable carrier, at least one pharmaceutically acceptable additive selected from the group consisting of fillers, extenders, binders, disintegrating agents, dissolution aids/accelerators, suspending agents, emulsifying agents, wetting agents, stabilizers, and preservatives.

23. A method of inhibiting activated blood coagulation factor X comprising administering to a mammal in need thereof a effective amount of the composition according to claim 17.

24. The method according to claim 23, wherein said effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

25. The method according to claim 23, wherein said effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

26. The method according to claim 23, wherein the administration of said composition ranges from one to four times per day.

27. A method of treating thrombosis or embolism comprising administering to a mammal in need thereof a effective amount of the composition according to claim 17.

28. The method according to claim 27, wherein said effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

29. The method according to claim 27, wherein said effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

30. The method according to claim 27, wherein the administration of said composition ranges from one to four times per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc